A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
Public ClinicalTrials.gov record NCT00159913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension.
Study identification
- NCT ID
- NCT00159913
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 235 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Sildenafil citrate Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 17 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2003
- Primary completion
- May 31, 2008
- Completion
- May 31, 2008
- Last update posted
- Feb 17, 2021
2003 – 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Palo Alto | California | 94304 | — |
| Pfizer Investigational Site | Stanford | California | 94305 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80045 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43205 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29425 | — |
| Pfizer Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00159913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2021 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00159913 live on ClinicalTrials.gov.